MA55068A - Co-agonistes des récepteurs du glucagon et du glp-1 - Google Patents

Co-agonistes des récepteurs du glucagon et du glp-1

Info

Publication number: MA55068A
Authority: MA; Morocco
Prior art keywords: glp; glucagon; agonists; receptor
Prior art date: 2014-10-24

Application number

MA055068A

Other languages

English (en)

Inventor

Elisabetta Bianchi

Paul E Carrington

Qiaolin Deng

Ravi Nargund

Federica Orvieto

Anandan Palani

Antonello Pessi

Thomas Joseph Tucker

Chengwei Wu

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-24

Filing date

2015-10-22

Publication date

2022-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54397022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55068(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-22 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2022-01-05 Publication of MA55068A publication Critical patent/MA55068A/fr

Links

102000051325 Glucagon Human genes 0.000 title 1
108010063919 Glucagon Receptors Proteins 0.000 title 1
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
239000000556 agonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA055068A 2014-10-24 2015-10-22 Co-agonistes des récepteurs du glucagon et du glp-1 MA55068A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462068157P	2014-10-24	2014-10-24
US201562208869P	2015-08-24	2015-08-24

Publications (1)

Publication Number	Publication Date
MA55068A true MA55068A (fr)	2022-01-05

Family

ID=54397022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA055068A MA55068A (fr)	2014-10-24	2015-10-22	Co-agonistes des récepteurs du glucagon et du glp-1

Country Status (25)

Country	Link
US (2)	US10413593B2 (fr)
EP (2)	EP3209682B1 (fr)
JP (1)	JP6581656B2 (fr)
KR (1)	KR101996739B1 (fr)
CN (1)	CN107108715A (fr)
AU (1)	AU2015335828B2 (fr)
CA (2)	CA2964379C (fr)
CL (1)	CL2017000982A1 (fr)
CO (1)	CO2017003832A2 (fr)
CR (1)	CR20170164A (fr)
DO (1)	DOP2017000102A (fr)
EA (1)	EA201790914A1 (fr)
GT (1)	GT201700085A (fr)
IL (1)	IL251741A0 (fr)
MA (1)	MA55068A (fr)
MD (1)	MD20170055A2 (fr)
MX (1)	MX382408B (fr)
NI (1)	NI201700048A (fr)
PE (1)	PE20180158A1 (fr)
PH (1)	PH12017500761A1 (fr)
SG (1)	SG11201703238TA (fr)
SV (1)	SV2017005425A (fr)
TN (1)	TN2017000148A1 (fr)
TW (1)	TW201625672A (fr)
WO (1)	WO2016065090A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
PT3155017T (pt) *	2014-05-28	2024-05-14	Mederis Diabetes Llc	Farmacêuticos peptídicos melhorados para resistência à insulina
CN107108715A (zh)	2014-10-24	2017-08-29	默沙东公司	胰高血糖素和glp‑1受体的共激动剂
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3377521A4 (fr)	2015-10-27	2019-05-01	Merck Sharp & Dohme Corp.	Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1
US11352405B2 (en) *	2017-08-09	2022-06-07	Sanofi	GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
US11566057B2 (en) *	2017-09-25	2023-01-31	Merck Sharp & Dohme Llc	Long-acting co-agonists of the glucagon and GLP-1 receptors
US11419918B2 (en) *	2017-11-06	2022-08-23	Shenzhen Turier Biotech Co., Ltd.	Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
EP4506017A3 (fr) *	2018-01-03	2025-05-14	Mederis Diabetes, LLC	Composés pharmaceutiques peptidiques améliorés utilisés pour le traitement d'une stéatohépatite non alcoolique et d'autres troubles
WO2020071865A1 (fr) *	2018-10-04	2020-04-09	한미약품 주식회사	Utilisations thérapeutiques du glucagon et produit combiné comprenant celui-ci
CN111171135B (zh) *	2018-11-12	2023-04-07	天津药物研究院有限公司	具有双重受体激动作用的胰高血糖素衍生肽及其用途
JP7798573B2 (ja) *	2019-02-06	2026-01-14	エンジーンバイオサイエンシーズリミテッド	グルカゴン様ペプチド－１（ｇｌｐ－１）アゴニストのアナログ、その調製プロセスおよび使用
CN110684082B (zh) *	2019-10-08	2021-12-10	江苏诺泰澳赛诺生物制药股份有限公司	Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
EP3842061A1 (fr)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
EP3842060A1 (fr)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1
EP3842449A1 (fr)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
WO2021142733A1 (fr) *	2020-01-16	2021-07-22	Shanghai Benemae Pharmaceutical Corporation	Thérapie combinatoire comprenant du glp-1 et/ou des analogues de glp-1, et de l'insuline et/ou des analogues de l'insuline
KR20230005289A (ko)	2020-04-24	2023-01-09	베링거 인겔하임 인터내셔날 게엠베하	지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
CN114222755B (zh) *	2020-05-29	2024-06-11	北京拓界生物医药科技有限公司	Glp-1和gip受体双重激动剂化合物及其应用
CN114349828B (zh) *	2020-11-27	2023-12-08	江苏师范大学	Glp-1/胰高血糖素受体双重激动剂及其应用
WO2022117044A1 (fr) *	2020-12-03	2022-06-09	Sunshine Lake Pharma Co., Ltd.	Polypeptide agoniste du récepteur double glp-1/gcg et sa protéine de fusion
CN117202924A (zh)	2020-12-07	2023-12-08	斯皮特弗尔制药有限责任公司	使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CN112608378B (zh) *	2020-12-09	2023-09-08	江苏师范大学	一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
CN116891522B (zh) *	2022-04-01	2024-05-14	南京知和医药科技有限公司	一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
CN115536739B (zh) *	2022-07-04	2023-04-14	北京惠之衡生物科技有限公司	一种glp-1受体和gcg受体共激动多肽衍生物的制备方法
JP2025526148A (ja)	2022-08-18	2025-08-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療
WO2024098718A1 (fr) *	2022-11-07	2024-05-16	内蒙古博睿精创科技有限公司	Nouveau composé polypeptidique à action prolongée, composition et utilisation associée
CN118684758A (zh) *	2023-03-23	2024-09-24	上海民为生物技术有限公司	肠促胰岛素类似物及其应用
CN119954932B (zh) *	2025-04-10	2025-07-22	广州呼吸药物工程技术有限公司	一种含β-氨基酸的胰高血糖素类似物或其药学上可接受的盐及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69819311T2 (de)	1997-03-07	2004-07-29	Metabasis Therapeutics Inc., San Diego	Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
US6054587A (en)	1997-03-07	2000-04-25	Metabasis Therapeutics, Inc.	Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6613942B1 (en)	1997-07-01	2003-09-02	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
BR9810378A (pt)	1997-07-01	2000-08-29	Novo Nordisk As	Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
KR100818845B1 (ko)	1998-09-09	2008-04-01	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
DE60023492T2 (de)	1999-05-17	2006-07-20	Novo Nordisk A/S	Glucagon antagonisten/inverse agonisten
JP4716641B2 (ja) *	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
AU7705601A (en)	2000-07-25	2002-02-05	Merck & Co Inc	N-substituted indoles useful in the treatment of diabetes
EP1357908A4 (fr)	2001-01-30	2009-07-15	Merck & Co Inc	Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
US7041646B2 (en) *	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
IL161677A0 (en)	2001-11-08	2004-09-27	Protein Design Labs	Stable liquid pharmaceutical formulation of igg antibodies
WO2003103572A2 (fr)	2002-06-04	2003-12-18	Eli Lilly And Company	Analogues modifies du peptide-1 de type glucagon (glp-1)
AR040241A1 (es)	2002-06-10	2005-03-23	Merck & Co Inc	Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP1546142A4 (fr)	2002-08-29	2007-10-17	Merck & Co Inc	Indoles presentant un effet antidiabetique
CN100457730C (zh)	2002-08-29	2009-02-04	默克公司	具有抗糖尿病活性的吲哚化合物
JO2397B1 (en)	2002-12-20	2007-06-17	ميرك شارب اند دوم كوربوريشن	Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
AU2004207444B2 (en)	2003-01-17	2008-07-31	Merck & Co., Inc.	N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
ES2569409T3 (es)	2005-03-08	2016-05-10	Pfizer Products Inc.	Composiciones de anticuerpo anti-CTLA-4
ATE553124T1 (de)	2005-06-13	2012-04-15	Imp Innovations Ltd	Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
CA2913805A1 (fr)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
US8175737B2 (en)	2006-07-19	2012-05-08	Freescale Semiconductor, Inc.	Method and apparatus for designing and integrated circuit
CL2007003583A1 (es)	2006-12-11	2008-07-18	Hoffmann La Roche	Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
RU2477286C2 (ru)	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2674608A1 (fr)	2007-01-09	2008-07-17	Wyeth	Preparations d'anticorps ant-il-13 et leurs utilisations
CA2677932A1 (fr)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Co-agonistes des recepteurs du glucagon/glp-1
EP2136814A4 (fr)	2007-03-21	2012-05-30	Univ Duke	Trousses de médication et formulations pour prévenir, traiter ou réduire des fractures secondaires après une fracture antérieure
CN101743616B (zh)	2007-06-28	2012-02-22	株式会社半导体能源研究所	半导体装置的制造方法
CA2691010A1 (fr)	2007-06-28	2008-12-31	Merck Frosst Canada Ltd.	Pyrimidines fusionnees substituees en tant qu'antagonistes de l'activite de gpr105
EP2178537A4 (fr)	2007-07-19	2011-08-17	Merck Sharp & Dohme	Dérivés de bêta-carboline en tant que composés antidiabétiques
US20110301079A1 (en)	2007-09-21	2011-12-08	Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Neuromedin u receptor agonists and uses thereof
ES2509883T3 (es)	2007-10-30	2014-10-20	Indiana University Research And Technology Corporation	Antagonistas de glucagón
MX2010004298A (es)	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2249853A4 (fr)	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	Promédicaments peptidiques à base d' esters
US8450270B2 (en)	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh)	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) *	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
WO2013019212A1 (fr)	2011-08-02	2013-02-07	Nano3D Biosciences, Inc.	Matériel pour la culture magnétique 3d
PE20120332A1 (es) *	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida
WO2010096052A1 (fr)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Analogues d'oxyntomoduline
EP2443146B1 (fr)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Composés de glucagon actifs sur le récepteur gip
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US8703701B2 (en) *	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
AR081434A1 (es)	2010-06-10	2012-08-29	Lilly Co Eli	Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
EP2585102B1 (fr)	2010-06-24	2015-05-06	Indiana University Research and Technology Corporation	Promédicaments insuliniques à base d'amide
EP2588126A4 (fr)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	Promédicaments peptidiques à base d'amides de la superfamille du glucagon
WO2011163473A1 (fr)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
WO2012088379A2 (fr)	2010-12-22	2012-06-28	Marcadia Biotech, Inc.	Méthodes de traitement des affections métaboliques et de l'obésité faisant appel à des peptides associés au glucagon, actifs sur les récepteurs gip et glp-1
EP2685826B1 (fr)	2011-03-18	2016-02-03	Merck Sharp & Dohme Corp.	Pipéridinone carboxamide spirohydantoïne, antagonistes du récepteur cgrp
WO2012150503A2 (fr) *	2011-05-03	2012-11-08	Zealand Pharma A/S	Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
KR20140043793A (ko) *	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr) *	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
US20130090285A1 (en) *	2011-06-27	2013-04-11	Phasebio Pharmaceuticals, Inc.	Methods of treatment with glp-1 receptor agonists
PE20150863A1 (es)	2012-06-21	2015-06-11	Univ Indiana Res & Tech Corp	Analogos de glucagon que exhiben actividad de receptor de gip
BR112015017619A2 (pt)	2013-01-24	2017-11-21	Glaxosmithkline Ip Dev Ltd	formulação líquida, uso de uma formulação, e, kit
CN107108715A (zh)	2014-10-24	2017-08-29	默沙东公司	胰高血糖素和glp‑1受体的共激动剂

2015
- 2015-10-22 CN CN201580070222.3A patent/CN107108715A/zh active Pending
- 2015-10-22 PE PE2017001204A patent/PE20180158A1/es unknown
- 2015-10-22 CA CA2964379A patent/CA2964379C/fr active Active
- 2015-10-22 KR KR1020177013556A patent/KR101996739B1/ko active Active
- 2015-10-22 MD MDA20170055A patent/MD20170055A2/ro not_active Application Discontinuation
- 2015-10-22 MX MX2017005280A patent/MX382408B/es unknown
- 2015-10-22 AU AU2015335828A patent/AU2015335828B2/en active Active
- 2015-10-22 MA MA055068A patent/MA55068A/fr unknown
- 2015-10-22 TW TW104134741A patent/TW201625672A/zh unknown
- 2015-10-22 CA CA3093383A patent/CA3093383A1/fr not_active Abandoned
- 2015-10-22 CR CR20170164A patent/CR20170164A/es unknown
- 2015-10-22 TN TN2017000148A patent/TN2017000148A1/en unknown
- 2015-10-22 US US15/519,565 patent/US10413593B2/en active Active
- 2015-10-22 EP EP15790398.0A patent/EP3209682B1/fr active Active
- 2015-10-22 JP JP2017521548A patent/JP6581656B2/ja active Active
- 2015-10-22 EP EP20212705.6A patent/EP3825324A1/fr active Pending
- 2015-10-22 WO PCT/US2015/056794 patent/WO2016065090A1/fr not_active Ceased
- 2015-10-22 SG SG11201703238TA patent/SG11201703238TA/en unknown
- 2015-10-22 US US14/920,012 patent/US20160114000A1/en not_active Abandoned
- 2015-10-22 EA EA201790914A patent/EA201790914A1/ru unknown
2017
- 2017-04-13 IL IL251741A patent/IL251741A0/en unknown
- 2017-04-20 CO CONC2017/0003832A patent/CO2017003832A2/es unknown
- 2017-04-20 CL CL2017000982A patent/CL2017000982A1/es unknown
- 2017-04-21 NI NI201700048A patent/NI201700048A/es unknown
- 2017-04-24 GT GT201700085A patent/GT201700085A/es unknown
- 2017-04-24 SV SV2017005425A patent/SV2017005425A/es unknown
- 2017-04-24 DO DO2017000102A patent/DOP2017000102A/es unknown
- 2017-04-24 PH PH12017500761A patent/PH12017500761A1/en unknown

Also Published As

Publication number	Publication date
PH12017500761A1 (en)	2017-10-09
CR20170164A (es)	2017-08-29
MX2017005280A (es)	2017-08-15
CA3093383A1 (fr)	2016-04-28
CN107108715A (zh)	2017-08-29
US20170360893A1 (en)	2017-12-21
AU2015335828A1 (en)	2017-05-11
SV2017005425A (es)	2018-04-04
PE20180158A1 (es)	2018-01-18
TN2017000148A1 (en)	2018-10-19
US20160114000A1 (en)	2016-04-28
KR20170073638A (ko)	2017-06-28
KR101996739B1 (ko)	2019-10-01
EA201790914A1 (ru)	2017-08-31
CA2964379C (fr)	2023-08-15
US10413593B2 (en)	2019-09-17
CA2964379A1 (fr)	2016-04-28
AU2015335828B2 (en)	2018-08-23
MX382408B (es)	2025-03-13
MD20170055A2 (ro)	2017-09-30
WO2016065090A1 (fr)	2016-04-28
EP3209682B1 (fr)	2020-12-30
EP3825324A1 (fr)	2021-05-26
DOP2017000102A (es)	2017-07-15
SG11201703238TA (en)	2017-05-30
JP2017537068A (ja)	2017-12-14
TW201625672A (zh)	2016-07-16
JP6581656B2 (ja)	2019-09-25
BR112017008160A8 (pt)	2023-04-11
CO2017003832A2 (es)	2017-06-30
IL251741A0 (en)	2017-06-29
BR112017008160A2 (pt)	2018-03-06
NI201700048A (es)	2017-06-12
CL2017000982A1 (es)	2017-11-10
GT201700085A (es)	2018-11-27
EP3209682A1 (fr)	2017-08-30

Publication	Publication Date	Title
MA55068A (fr)	2022-01-05	Co-agonistes des récepteurs du glucagon et du glp-1
IL285231A (en)	2021-09-30	Co-agonistic compounds for glucagon and glp-1
DK3555064T3 (da)	2022-12-12	GLP-1 receptoragonister og anvendelser deraf
DK3126381T4 (da)	2022-04-04	Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK3210977T3 (da)	2019-07-01	Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
IL249373A0 (en)	2017-02-28	Polypeptide formulations of related detector and method
DK3215147T3 (da)	2024-04-02	Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3169703T3 (da)	2020-11-16	Kimær antigenreceptor og anvendelse deraf
DK3183880T3 (da)	2021-05-03	Samling af intra-blok-kopi og interprædiktion
DK3218358T3 (da)	2021-08-30	Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
MA50474A (fr)	2020-09-02	Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1
DK3212218T3 (da)	2021-08-30	GIP-agonistforbindelser og fremgangsmåder
DK3015526T3 (da)	2021-01-18	Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3233903T3 (da)	2021-02-22	Kimære antigenreceptorer og anvendelsesfremgangsmåder
EP3394091A4 (fr)	2019-12-18	Co-agonistes des récepteurs de glucagon et de glp-1
DK3098281T3 (da)	2020-10-19	Sammensætning omfattende hfc og hfo
UA31197S (uk)	2016-01-12	Таблетка
DK3126791T3 (da)	2020-06-02	Doseringsanordning
DK3406264T3 (da)	2022-02-28	Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf
FI20145379A7 (fi)	2015-10-25	Torrefiointilaite
DK3140050T3 (da)	2023-05-22	Dosering med visning
DOS2015000092S (es)	2016-04-15	Pantalla
DK3107376T3 (da)	2025-01-13	Svampelinje b12998-s39 og fremgangsmåder dertil og anvendelser herfor
DK3134701T3 (da)	2019-07-08	Projektilstoppende indretning og projektilstoppende anordning
DK2910786T3 (da)	2019-10-14	Roterbart apparat